There is exciting news for people living with pulmonary arterial hypertension (PAH). A new medication called ralinepag has shown strong results in a large clinical trial. PAH is a serious disease that causes high blood pressure in the blood vessels of the lungs. Over time, this makes the heart work harder and can lead to heart failure. What Is … [Read more...]
Sotatercept: ZENITH and HYPERION Trials
Sotatercept, the newest drug approved to treat pulmonary arterial hypertension (PAH) has been on the market Since May of 2024. In the phase 2 PULSAR trial and phase 3 STELLAR trial, sotatercept delivered impressive results, lowering pulmonary artery pressures, improving exercise capacity and leading to improvement in risk status and improved right heart function. Merck … [Read more...]
Sotatercept Coming Soon
A new drug is poised to enter the PAH market and offers great promise for patients. This new drug works in a completely different way from all the currently approved medications. Sotatercept is an injection (shot) that is given subcutaneously (under the skin) every 3 weeks. The medication acts by blocking activin. In PAH there are good signals and bad signals within the blood … [Read more...]
Aerovate and Inhaled Imatinib
Imatinib is a tyrosine kinase inhibitor that has been on the market for more than 20 years to treat a type of leukemia. It acts by turning off tyrosine kinases. You can think of tyrosine kinases as critical switches in cells that turn on and off critical pathways. Too much of an “on” signal leads to dysregulated cell proliferation and growth—such as seen … [Read more...]
Sotatercept for Pulmonary Arterial Hypertension
For the past 30 years, all our pulmonary arterial hypertension medications were described as vasodilators: First prostanoids (epoprostenol), then endothelin receptor antagonists (bosentan, ambrisentan, macitentan) and PDE5 inhibitors (sildenafil and tadalafil). These medications work through different mechanism but all lead to the vasodilation or … [Read more...]
